comparemela.com
  1. Home
  2. Live Updates
  3. Promising Investigational Safety Record - Breaking News

Latest Breaking News On - Promising investigational safety record - Page 1 : comparemela.com

Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings

AUSTIN, Texas, April 18, 2024 Lumos Pharma, Inc. , a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency through Phase 2 clinical trials,.

StockholmSwedenChicagoIllinoisUnited statesUkraineRussiaTexasJ clin endocrinolLisa millerPeter claytonLumos pharmaErick hawkinsAndrew dauberEuropean congressNasdaq

Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings

18.04.2024 - AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) - Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today . Seite 1

SwedenStockholmAndrew dauberPeter claytonEuropean congressInternational congressGrowth hormone research societySimilar annualized height velocityModerate pediatric growth hormone deficiencyPromising investigational safety recordPediatric growth hormone deficiency

Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings

AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic ca.

RussiaSwedenUkraineChicagoIllinoisUnited statesStockholmTexasErick hawkinsPeter claytonLumos pharmaJ clin endocrinolLisa millerAndrew dauberNasdaqPediatric endocrine society

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.